MiniMed Surpasses $3 Billion in Revenue as First Publicly Traded Insulin Pump Manufacturer
MiniMed, a leading manufacturer of insulin pumps and automated insulin delivery systems, has made history by surpassing the $3 billion mark in revenue for fiscal 2026. This significant milestone was achieved through the company's focus on driving pipeline execution over the last few years.
In its first quarter as a standalone publicly traded company, MiniMed demonstrated robust performance across various markets. The company's record-breaking revenue growth was driven by strong international market sales and sequential pump adoption momentum in the United States. New sensors played a significant role in propelling this growth throughout the second half of fiscal 2026.
"We're proud to have achieved this milestone, which reflects our dedication to empowering people living with insulin-dependent diabetes," said Que Dallara, Chief Executive Officer of MiniMed. "Our automated insulin delivery platform has been a game-changer for millions worldwide, and we're committed to expanding access to this life-changing technology."
MiniMed's revenue growth was fueled by the company's ability to execute on its pipeline plans. The successful launch of new products, such as the MiniMed Flex and Instinct sensor made in collaboration with Abbott, contributed significantly to this success. Additionally, the company's ongoing efforts to expand access to its technology have yielded impressive results.
International market sales played a crucial role in driving revenue growth for the company. The adoption of insulin pumps and automated insulin delivery systems has become increasingly popular globally, driven by growing awareness and understanding of the benefits of these technologies among healthcare professionals and patients alike.
In the United States, MiniMed witnessed sequential pump adoption momentum in Q4 2026, indicating a promising trend for future growth. Although revenue growth was slightly below expectations in this market, the company remains optimistic about its prospects.
"We recognize that we have an opportunity to make a meaningful difference in the lives of people living with diabetes," said Que Dallara. "Our focus on innovation and execution has positioned us well for continued success."
